Mornings Earnings Wrap Up for Thursday, March 16, 2023
Top Earnings News
Dollar General Reported In-line with Expectations
Dollar General (DG) reported earnings of $2.96 per share on revenue of $10.20 billion for the fiscal fourth quarter ended January 2023. The consensus earnings estimate was $2.94 per share on revenue of $10.32 billion. The Earnings Whisper number was $2.96 per share. The company reported in-line with expectations while revenue grew 17.93% on a year-over-year basis.
The company said it expects fiscal 2024 earnings of $11.11 to $11.32 per share on revenue of $39.93 billion to $40.12 billion. The current consensus earnings estimate is $11.27 per share on revenue of $40.11 billion for the year ending January 31, 2024.
Dollar General Corp is a discount retailer in the United States, which offers a selection of merchandise, including consumables, seasonal, home products and apparel.
Jabil Missed Expectations
Jabil (JBL) reported earnings of $1.88 per share on revenue of $8.13 billion for the fiscal second quarter ended February 2023. The consensus earnings estimate was $1.85 per share on revenue of $8.10 billion. The Earnings Whisper number was $1.90 per share. The company missed expectations by 1.05% while revenue grew 7.69% on a year-over-year basis.
The company said it expects third quarter non-GAAP earnings of $1.70 to $2.10 per share on revenue of $7.90 billion to $8.50 billion. The current consensus earnings estimate is $1.92 per share on revenue of $8.17 billion for the quarter ending May 31, 2023. The company also said it expects fiscal 2023 revenue of approximately $34.50 billion. The current consensus revenue estimate is $34.51 billion for the year ending August 31, 2023.
Jabil Circuit Inc, together with its subsidiaries is a provider of electronic manufacturing services and solutions. It provides electronic design, production &product management services to companies in the aerospace, automotive, & among others.
Top Earnings Surprise
Designer Brands Beat Expectations
Designer Brands (DBI) reported earnings of $0.07 per share on revenue of $760.55 million for the fiscal fourth quarter ended January 2023. The consensus estimate was a loss of $0.02 per share on revenue of $797.90 million. The Earnings Whisper number was $0.01 per share. The company beat expectations by 600.00% while revenue fell 7.55% compared to the same quarter a year ago.
The company said it expects fiscal 2024 earnings of $1.65 to $1.75 per share. The current consensus earnings estimate is $1.89 per share for the year ending January 31, 2024.
Designer Brands Inc. is one of North America's largest designers, producers and retailers of footwear and accessories.
Top Negative Surprise
Paratek Pharmaceuticals Missed Consensus Estimates
Paratek Pharmaceuticals (PRTK) reported a loss of $0.12 per share on revenue of $75.56 million for the fourth quarter ended December 2022. The consensus earnings estimate was $0.01 per share on revenue of $63.45 million. The company missed consensus estimates by 1,300.00% while revenue grew 137.62% on a year-over-year basis.
The company said it expects 2023 revenue of $143.0 million to $158.0 million. The current consensus revenue estimate is $232.02 million for the year ending December 31, 2023.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
Top Revenue Growth
IMV Missed Consensus Estimates
IMV (IMV) reported a loss of $0.99 per share on revenue of $0.15 million for the fourth quarter ended December 2022. The consensus estimate was a loss of $0.92 per share on revenue of $0.03 million. The company missed consensus estimates by 7.61% while revenue grew 337.14% on a year-over-year basis.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary delivery platform (DPX). This patented technology leverages a novel mechanism of action that enables the activation of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing DPX-Survivac in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.
Top Positive Guidance
KE Beat Consensus Estimates
KE (BEKE) reported earnings of $0.11 per share on revenue of $2.43 billion for the fourth quarter ended December 2022. The consensus earnings estimate was $0.03 per share on revenue of $2.31 billion. The company beat consensus estimates by 266.67% while revenue fell 13.00% compared to the same quarter a year ago.
The company said it expects first quarter revenue of $2.60 billion to $2.70 billion. The current consensus revenue estimate is $2.03 billion for the quarter ending March 31, 2023.
KE Holdings Inc. is the leading integrated online and offline platform for China’s housing transactions and services. The Company is a pioneer in building the industry infrastructure and standards in China to reinvent how service providers and housing customers efficiently navigate and consummate housing transactions, ranging from existing and new home sales, home rentals, to home renovation, real estate financial solutions, and other services. The Company owns and operates Lianjia, China’s leading real estate brokerage brand and an integral part of its Beike platform.